Gilead falls on earnings miss; Sales of hepatitis C drugs below estimates
April 28, 2016 at 16:09 PM EDT
Analysts expected Gilead to report earnings of about $3.15 a share on $8.12 billion in revenue, according to a consensus estimate from Thomson Reuters.
